U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry RACEMIC
Molecular Formula C19H31F3NO6P
Molecular Weight 457.4215
Optical Activity ( + / - )
Defined Stereocenters 0 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of Amiselimod phosphate

SMILES

CCCCCCCOC1=C(C=C(CCC(N)(CO)COP(O)(O)=O)C=C1)C(F)(F)F

InChI

InChIKey=OFRUGVQKZMGHHH-UHFFFAOYSA-N
InChI=1S/C19H31F3NO6P/c1-2-3-4-5-6-11-28-17-8-7-15(12-16(17)19(20,21)22)9-10-18(23,13-24)14-29-30(25,26)27/h7-8,12,24H,2-6,9-11,13-14,23H2,1H3,(H2,25,26,27)

HIDE SMILES / InChI
Amiselimod (MT-1303) is a selective sphingosine 1-phosphate 1 (S1P1 ) receptor modulator which is currently being developed for the treatment of various autoimmune diseases. Unlike some other S1P receptor modulators, amiselimod seemed to show a favourable cardiac safety profile in preclinical, phase I and II studies. Amiselimod may be potentially useful for treatment of multiple sclerosis; inflammatory diseases; autoimmune diseases; psoriasis and inflammatory bowel diseases. Amiselimod is currently being developed by Mitsubishi Tanabe Pharma Corporation.

Approval Year

Sourcing

Sourcing

Vendor/AggregatorIDURL
PubMed

PubMed

TitleDatePubMed
Evaluation and Optimization of in silico designed Sphingosine-1-Phosphate (S1P) Receptor Subtype 1 Modulators for the Management of Multiple Sclerosis.
2017 Mar
Cardiac effects of amiselimod compared with fingolimod and placebo: results of a randomised, parallel-group, phase I study in healthy subjects.
2017 May
Two-year results from a phase 2 extension study of oral amiselimod in relapsing multiple sclerosis.
2018 Oct
Patents

Patents

Sample Use Guides

A total of 81 healthy subjects aged 18-55 years were equally randomized to receive amiselimod 0.4 mg, amiselimod 0.8 mg, placebo or fingolimod 0.5 mg once daily for 28 days.
Route of Administration: Oral
HEK293 cells or HCMs were plated onto 48-well culture plates, cultured overnight and then incubated with 100 nmol/L of amiselimod for 3–12 h.
Name Type Language
Amiselimod phosphate
Common Name English
Amiselimod-P
Common Name English
2-Amino-4-(4-heptyloxy-3-trifluoromethylphenyl)-2-[(phosphonooxy)methyl]butanol
Systematic Name English
1,3-Propanediol, 2-amino-2-[2-[4-(heptyloxy)-3-(trifluoromethyl)phenyl]ethyl]-, 1-(dihydrogen phosphate)
Systematic Name English
Code System Code Type Description
PUBCHEM
23581980
Created by admin on Fri Jul 07 00:54:06 UTC 2023 , Edited by admin on Fri Jul 07 00:54:06 UTC 2023
PRIMARY
FDA UNII
QL6WNR6C4D
Created by admin on Fri Jul 07 00:54:06 UTC 2023 , Edited by admin on Fri Jul 07 00:54:06 UTC 2023
PRIMARY
CAS
942398-85-8
Created by admin on Fri Jul 07 00:54:06 UTC 2023 , Edited by admin on Fri Jul 07 00:54:06 UTC 2023
PRIMARY